FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902301444> ?p ?o ?g. }

• W2902301444 endingPage "687" @default.
• W2902301444 startingPage "676" @default.
• W2902301444 abstract "Abstract Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and impaired hematopoietic differentiation. Enasidenib is an oral inhibitor of mutant-IDH2 proteins. This first-in-human phase 1/2 study evaluated enasidenib doses of 50 to 650 mg/d, administered in continuous 28-day cycles, in patients with mutant-IDH2 hematologic malignancies. Overall, 214 of 345 patients (62%) with relapsed or refractory (R/R) AML received enasidenib, 100 mg/d. Median age was 68 years. Forty-two patients (19.6%) attained complete remission (CR), 19 patients (10.3%) proceeded to an allogeneic bone marrow transplant, and the overall response rate was 38.8% (95% confidence interval [CI], 32.2-45.7). Median overall survival was 8.8 months (95% CI, 7.7-9.6). Response and survival were comparable among patients with IDH2-R140 or IDH2-R172 mutations. Response rates were similar among patients who, at study entry, were in relapse (37.7%) or were refractory to intensive (37.5%) or nonintensive (43.2%) therapies. Sixty-six (43.1%) red blood cell transfusion–dependent and 53 (40.2%) platelet transfusion–dependent patients achieved transfusion independence. The magnitude of 2-HG reduction on study was associated with CR in IDH2-R172 patients. Clearance of mutant-IDH2 clones was also associated with achievement of CR. Among all 345 patients, the most common grade 3 or 4 treatment-related adverse events were hyperbilirubinemia (10%), thrombocytopenia (7%), and IDH differentiation syndrome (6%). Enasidenib was well tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed. The study is registered at www.clinicaltrials.gov as #NCT01915498." @default.
• W2902301444 created "2018-12-11" @default.
• W2902301444 creator A5000959540 @default.
• W2902301444 creator A5001124933 @default.
• W2902301444 creator A5005718112 @default.
• W2902301444 creator A5010057352 @default.
• W2902301444 creator A5010786159 @default.
• W2902301444 creator A5012709994 @default.
• W2902301444 creator A5012863731 @default.
• W2902301444 creator A5017435311 @default.
• W2902301444 creator A5018048721 @default.
• W2902301444 creator A5018488202 @default.
• W2902301444 creator A5020684790 @default.
• W2902301444 creator A5025660159 @default.
• W2902301444 creator A5025780450 @default.
• W2902301444 creator A5032549755 @default.
• W2902301444 creator A5053081930 @default.
• W2902301444 creator A5053897548 @default.
• W2902301444 creator A5055740968 @default.
• W2902301444 creator A5060321112 @default.
• W2902301444 creator A5063041606 @default.
• W2902301444 creator A5066934816 @default.
• W2902301444 creator A5071023119 @default.
• W2902301444 creator A5075397421 @default.
• W2902301444 creator A5076534799 @default.
• W2902301444 creator A5078877351 @default.
• W2902301444 creator A5089074892 @default.
• W2902301444 creator A5089274301 @default.
• W2902301444 creator A5090435894 @default.
• W2902301444 date "2019-02-14" @default.
• W2902301444 modified "2023-10-11" @default.
• W2902301444 title "Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib" @default.
• W2902301444 cites W174683914 @default.
• W2902301444 cites W1881046587 @default.
• W2902301444 cites W1982766090 @default.
• W2902301444 cites W1992607388 @default.
• W2902301444 cites W1995675594 @default.
• W2902301444 cites W2008682627 @default.
• W2902301444 cites W2012588998 @default.
• W2902301444 cites W2053937610 @default.
• W2902301444 cites W2078972833 @default.
• W2902301444 cites W2080452140 @default.
• W2902301444 cites W2097192169 @default.
• W2902301444 cites W2101590448 @default.
• W2902301444 cites W2106789440 @default.
• W2902301444 cites W2123222392 @default.
• W2902301444 cites W2130937042 @default.
• W2902301444 cites W2134519717 @default.
• W2902301444 cites W2159507916 @default.
• W2902301444 cites W2159746057 @default.
• W2902301444 cites W2164219809 @default.
• W2902301444 cites W2320554446 @default.
• W2902301444 cites W2419140434 @default.
• W2902301444 cites W2559537906 @default.
• W2902301444 cites W2588292471 @default.
• W2902301444 cites W2588385654 @default.
• W2902301444 cites W2593230508 @default.
• W2902301444 cites W2604214351 @default.
• W2902301444 cites W2623089849 @default.
• W2902301444 cites W2624245118 @default.
• W2902301444 cites W2725930552 @default.
• W2902301444 cites W2761653381 @default.
• W2902301444 cites W2787911840 @default.
• W2902301444 cites W4231346141 @default.
• W2902301444 cites W4376595466 @default.
• W2902301444 doi "https://doi.org/10.1182/blood-2018-08-869008" @default.
• W2902301444 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6384189" @default.
• W2902301444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30510081" @default.
• W2902301444 hasPublicationYear "2019" @default.
• W2902301444 type Work @default.
• W2902301444 sameAs 2902301444 @default.
• W2902301444 citedByCount "246" @default.
• W2902301444 countsByYear W29023014442019 @default.
• W2902301444 countsByYear W29023014442020 @default.
• W2902301444 countsByYear W29023014442021 @default.
• W2902301444 countsByYear W29023014442022 @default.
• W2902301444 countsByYear W29023014442023 @default.
• W2902301444 crossrefType "journal-article" @default.
• W2902301444 hasAuthorship W2902301444A5000959540 @default.
• W2902301444 hasAuthorship W2902301444A5001124933 @default.
• W2902301444 hasAuthorship W2902301444A5005718112 @default.
• W2902301444 hasAuthorship W2902301444A5010057352 @default.
• W2902301444 hasAuthorship W2902301444A5010786159 @default.
• W2902301444 hasAuthorship W2902301444A5012709994 @default.
• W2902301444 hasAuthorship W2902301444A5012863731 @default.
• W2902301444 hasAuthorship W2902301444A5017435311 @default.
• W2902301444 hasAuthorship W2902301444A5018048721 @default.
• W2902301444 hasAuthorship W2902301444A5018488202 @default.
• W2902301444 hasAuthorship W2902301444A5020684790 @default.
• W2902301444 hasAuthorship W2902301444A5025660159 @default.
• W2902301444 hasAuthorship W2902301444A5025780450 @default.
• W2902301444 hasAuthorship W2902301444A5032549755 @default.
• W2902301444 hasAuthorship W2902301444A5053081930 @default.
• W2902301444 hasAuthorship W2902301444A5053897548 @default.
• W2902301444 hasAuthorship W2902301444A5055740968 @default.
• W2902301444 hasAuthorship W2902301444A5060321112 @default.
• W2902301444 hasAuthorship W2902301444A5063041606 @default.
• W2902301444 hasAuthorship W2902301444A5066934816 @default.

• next